Market Overview

Akorn Shares Rally Following Increased Price Target

Share:
Related AKRX
Drug Price Hike Concerns Spill Over Into Other Pharma Stocks
Benzinga's Top Downgrades

Shares of Akorn (NASDAQ: AKRX) were up nearly 10 percent Tuesday around $36.50 following the release of a Needham note in which the price target for the company was raised from $30 to $40.

The note cited a "game changing" effect if Akorn matches Taro Pharmaceutical Industries' recent price increases in topical generics.

Shares are currently up 5.25 percent at $34.99.

Latest Ratings for AKRX

DateFirmActionFromTo
Aug 2016Deutsche BankDowngradesBuyHold
Aug 2016Raymond JamesDowngradesOutperformMarket Perform
Mar 2016Leerink SwannMaintainsMarket Perform

View More Analyst Ratings for AKRX
View the Latest Analyst Ratings

Posted-In: NeedhamAnalyst Color News Price Target Analyst Ratings

 

Related Articles (AKRX)

View Comments and Join the Discussion!